c-Triadem: A constrained, explainable deep learning model to identify novel biomarkers in Alzheimer’s disease
Authors:
Open Access
- 14 April 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0320360
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that requires early diagnosis for effective management. However, issues with currently available diagnostic biomarkers preclude early diagnosis, necessitating the development of alternative biomarkers and methods, such as blood-based diagnostics. We propose c-Triadem (constrained triple-input Alzheimer’s disease model), a novel deep neural network to identify potential blood-based biomarkers for AD and predict mild cognitive impairment (MCI) and AD with high accuracy. The model utilizes genotyping data, gene expression data, and clinical information to predict the disease status of participants, i.e., cognitively normal (CN), MCI, or AD. The nodes of the neural network represent genes and their related pathways, and the edges represent known relationships among the genes and pathways. Simulated data validation further highlights the robustness of key features identified by SHapley Additive exPlanations (SHAP). We trained the model with blood genotyping data, microarray, and clinical features from the Alzheimer’s Neuroimaging Disease Initiative (ADNI). We demonstrate that our model’s performance is superior to previous models with an AUC of 97% and accuracy of 89%. We then identified the most influential genes and clinical features for prediction using SHapley Additive exPlanations (SHAP). Our SHAP analysis shows that CASP9, LCK, and SDC3 SNPs and PINK1, ATG5, and ubiquitin (UBB, UBC) expression have a higher impact on model performance. Our model has facilitated the identification of potential blood-based genetic markers of DNA damage response and mitophagy in affected regions of the brain. The model can be used for detection and biomarker identification in other related dementias.Keywords
All Related Versions
Funding Information
- Khalifa University of Science, Technology and Research (FSU-2021-005)
This publication has 55 references indexed in Scilit:
- Biomarkers in Alzheimer's Disease: A ReviewISRN Pharmacology, 2012
- A Blood-Based Algorithm for the Detection of Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2011
- Alzheimer's Disease Neuroimaging Initiative (ADNI)Neurology, 2010
- AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2009
- Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer diseaseJournal of the Neurological Sciences, 2005
- Results of a high-resolution genome screen of 437 Alzheimer's Disease familiesHuman Molecular Genetics, 2003
- Caspase-9 Activation and Caspase Cleavage of tau in the Alzheimer's Disease BrainNeurobiology of Disease, 2002
- Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late‐onset sporadic Alzheimer's diseasePsychiatry and Clinical Neurosciences, 2000
- Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's diseaseNeurology, 1992
- BETA-PROTEIN AMYLOID IS WIDELY DISTRIBUTED IN THE CENTRAL NERVOUS-SYSTEM OF PATIENTS WITH ALZHEIMERS-DISEASE1989